Alex D. Waldman

Alex D. Waldman

Auto-generated profile, based on publicly available information

Alex D. Waldman

Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Nature Reviews Immunology
Verified
Journal Article
Open access
PDF file
AWAlex D. Waldman
Alex D. Waldman
JFJill M. Fritz
Jill M. Fritz
MLMichael J. Lenardo
Michael J. Lenardo
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.

9 January 2019 in Neurochemistry International
Verified
Journal Article
Closed access
PCPelin Cengiz
Pelin Cengiz
DZDila Zafer
Dila Zafer
JCJayadevi H. Chandrashekhar
Jayadevi H. Chandrashekhar
VCVishal Chanana
Vishal Chanana
JBJacob Bogost
Jacob Bogost
PFPeter A. Ferrazzano
Peter A. Ferrazzano

7 March 2017 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
QBQian Bu
Qian Bu
AWAnxin Wang
Anxin Wang
HHHamdi Hamzah
Hamdi Hamzah
AWAlex Waldman
Alex Waldman
KJKeer Jiang
Keer Jiang
QCQiang Chang
Qiang Chang
Rett syndrome (RTT) is a debilitating neurodevelopmental disorder caused by mutations in theMECP2gene. To facilitate the study of cellular mechanisms in human cells, we established several human stem cell lines: human embryonic stem cell (hESC) line carrying the common T158M mutation (MECP2T158M/T158M), hESC line expressing no MECP2 (MECP2-KO), congenic pair of wild-type and mutant RTT patient-specific induced pluripotent stem cell (iPSC) line carrying the V247fs mutation (V247fs-WT and V247fs-MT), and iPSC line in which the V247fs mutation was corrected by CRISPR/Cas9-based genome editing (V247fs-MT-correction). Detailed analyses of forebrain neurons differentiated from these human stem cell lines revealed genotype-dependent quantitative phenotypes in neurite growth, dendritic complexity, and mitochondrial function. At the molecular level, we found a significant reduction in the level of CREB and phosphorylated CREB in forebrain neurons differentiated fromMECP2T158M/T158M,MECP2-KO, and V247fs-MT stem cell lines. Importantly, overexpression of CREB or pharmacological activation of CREB signaling in those forebrain neurons rescued the phenotypes in neurite growth, dendritic complexity, and mitochondrial function. Finally, pharmacological activation of CREB in the femaleMecp2heterozygous mice rescued several behavioral defects. Together, our study establishes a robustin vitroplatform for consistent quantitative evaluation of genotype-dependent RTT phenotypes, reveals a previously unappreciated role of CREB signaling in RTT pathogenesis, and identifies a potential therapeutic target for RTT.SIGNIFICANCE STATEMENTOur study establishes a robust human stem cell-based platform for consistent quantitative evaluation of genotype-dependent Rett syndrome (RTT) phenotypes at the cellular level. By providing the first evidence that enhancing cAMP response element binding protein signaling can alleviate RTT phenotypes bothin vitroandin vivo, we reveal a previously unappreciated role of cAMP response element binding protein signaling in RTT pathogenesis, and identify a potential therapeutic target for RTT.

1 February 2016 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
UCUlas Cikla
Ulas Cikla
VCVishal Chanana
Vishal Chanana
DKDouglas B. Kintner
Douglas B. Kintner
LCLucia Covert
Lucia Covert
TDTaylor Dewall
Taylor Dewall
PFPeter Ferrazzano
Peter Ferrazzano

22 December 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SKSatoshi Kubo
Satoshi Kubo
JFJill M. Fritz
Jill M. Fritz
HRHayley M. Raquer-McKay
Hayley M. Raquer-McKay
RKRhea Kataria
Rhea Kataria
IVIvan Vujkovic-Cvijin
Ivan Vujkovic-Cvijin
MLMichael J. Lenardo
Michael J. Lenardo

22 January 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Jim ZhongJim Zhong
Jim Zhong
AWAlex D. Waldman
Alex D. Waldman
SKShravan Kandula
Shravan Kandula
BEBree R. Eaton
Bree R. Eaton
RPRoshan S. Prabhu
Roshan S. Prabhu
HSHui-Kuo G. Shu
Hui-Kuo G. Shu